Related Experiment Video
Updated: Jun 8, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Safe insulin use in the hospital setting
1Oakland University William Beaumont School of Medicine, USA. schmeltz@endocrinemds.com
Hospital Practice (1995)
|September 30, 2010
Summary
Hospitalized patients with hyperglycemia benefit from effective glycemic control using insulin algorithms. This improves outcomes, reduces complications, and lowers costs, emphasizing the need for structured management protocols.
Area of Science:
- Internal Medicine
- Endocrinology
- Hospital Management
Background:
- High prevalence of diabetes (12-26%) and hyperglycemia (~38%) in inpatients.
- Glycemic control impacts mortality, complications, length of stay, and costs.
- Admission glycosylated hemoglobin (A1C) aids in differentiating hyperglycemia types.
Purpose of the Study:
- To outline strategies for optimal inpatient glycemic control.
- To emphasize the role of insulin algorithms and protocols.
- To highlight the benefits of good glycemic management.
Main Methods:
- Utilizing intravenous (IV) or subcutaneous (SC) insulin algorithms for hyperglycemia.
- Implementing a hypoglycemia management protocol for patient safety.
- Employing insulin analogues over human insulins for predictable profiles.
Main Results:
- Good glycemic control is linked to reduced mortality and complications.
- Effective management decreases hospital stay and healthcare expenses.
- Insulin algorithms facilitate safe transitions from IV to SC insulin.
Conclusions:
- Insulin algorithms, frequent monitoring, and clear protocols are crucial for inpatient glycemic control.
- Insulin analogues offer advantages in absorption and action predictability.
- Multifaceted approaches including education and safety protocols enhance safe insulin use.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...